



Affitech
Advancing Antibody Medicines

BioEurope
1st November 2011

Michael Braunagel
SDir Strategic Alliances and Licensing
Affitech A/S

Disclaimer

Forward Looking Statements

Affitech A/S is a public company listed on NASDAQ OMX Copenhagen. Recipients of this presentation are advised that this written presentation and any verbal comments to it provided by Executive Management contain forward looking statements, including without limitation those regarding Affitech's financial position, business strategy, news flow, plans and objectives for future operations, including development plans and objectives relating to our products. Such forward looking statements are based upon assumptions of future events which may not prove to be accurate and involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied by such forward looking statements. In addition, the forward looking statements in this document speak only as of the date of this presentation

A multicultural organization

30+ people, 27 scientists, 10 of which are PhDs

Experienced international executive management team:


- Managing Director Martin Welschhof, German, one of Affitech's founders
- CFO Stig Jarle Pettersen, Norwegian state authorized public accountant
- CSO Alexander Duncan, British, a leading antibody research scientist and business leader

Facilities in Copenhagen Bio Science Park , Denmark and in the Research Park in Oslo, Norway

Listed on Nasdaq OMX Copenhagen (AFFI)

Powerful technology drives discovery engine

Platform with high capacity to isolate multiple fully human antibody candidates to targets with challenging specificities



AT001/r84 – potential for greater safety

AT001/r84 antibody is a proprietary antibody with a novel mechanism of action:

- A fully human antibody
- Binds VEGF selectively, inhibiting binding to VEGFR2 only and not VEGFR1
- Preclinical data shows efficacy at least equal to Avastin® (bevacizumab)
- Shows limited induction of side effects

Large market opportunity for AT001/r84 in emerging markets :


- Potential to be a better “Avastin®”, which had sales of ~USD 5.9bn in 2009
- Low penetration of Avastin® in Russia/CIS
- An anti-VEGF antibody has top priority on Russian short list of innovative drugs to be marketed by 2015



Scheduled to enter phase I clinical trial in Russia in 2011


AT001/r84 – more specific inhibition (VEGF)

Avastin



AT001/r84

More selective for anti-angiogenesis




AT001/r84 progressing well

- First GMP manufacturing (through AVID) completed
- Preparing Clinical Trial Application for submission
- Collaboration agreement with Dr. Rolf Brekken (University of Texas Southwestern), for further mechanistic studies in disease models

GPCRs - major opportunity for antibody approach

- **G-protein coupled receptors (GPCRs) can be used where inhibition by small molecule chemistry has proven difficult**
- **Multi-ligand GPCRs can be targeted for antibody therapy**

- **GPCRs - the largest known protein family at >2% of the entire genome**
- **Involved in a wide range of disorders and biological functions**
- **~20% of current drugs target GPCRs but only a fraction of the cell surface receptors**



Antibodies to GPCRs – potential indications

- Primary tumors in both hematological cancers and solid tumors
- Metastatic lesions
- Regulatory T cells (in stroma and circulation)





AT008/CCR4 in progress

A potential development candidate has been identified

- Clinically validated target:
 - NDA filed in Japan for anti-CCR4 antibody KW-0761 to treat Adult T-cell Leukemia-Lymphoma (ATL) (Kyowa Hakko Kirin, partnered with Amgen)
- Preliminary proof of concept
- Several candidates interfering with the binding of the ligands to CCR4 identified
- Collaboration agreement with Professor Frances Balkwill, Cancer Research Technology Ltd. UK for further validation of the CCR4 target
- Six other chemokine receptor programs are being profiled in *in vitro* and *in vivo* models

Affitech's bispecific antibody program: BIMS

- BIMS – “Bispecific IgG-like Molecule of enhanced Selectivity”
- Next generation dual specificity/functionality antibody-like molecules
- BIMS is a molecule which has the size of a normal IgG antibody. Since it is tetravalent it has a longer half-life in circulation



Valuable strategic partnerships

IBC Generium



AT001/r84 and AT008. Fast track to market. Financing of clinical trials in Russia. Marketing in Russia and the other CIS countries. Affitech retains worldwide rights. Opportunity to leverage into other emerging markets

Collaboration on AT004 and AT005, in cancer and infectious diseases

AT006 / Ang-2 program. **Roche is using Affitech's Ang-2 antibody in a bi-specific format with Avastin®**

GMP Manufacturing for AT001/r84

Exploring further development partnerships in BRIC or other regions of the world

Excellent research collaborations



Cancer Research
Technology



- Research collaboration with Professor Frances Balkwill, Cancer Research Technology Ltd. UK for further validation of CCR4 target
- Research collaboration with Dr. Rolf Brekken, University of Texas Southwestern Medical Center, Dallas, USA for further mechanistic studies of AT001/r84 in disease models

Contact details

Affitech A/S
Copenhagen, Denmark
c/o COBIS
Ole Maaløes Vej 3
DK- 2200 Kbh. N
Denmark
Telephone: +45 39 17 82 59
Email: IR@affitech.comf

Affitech Research, Oslo, Norway
Gaustadalléen 21
N-0349 Oslo
Norway
Telephone: +47 22 95 87 58
Fax: +47 22 95 83 58
Email: INFO@affitech.com

WWW.affitech.com

***Affitech A/S addresses unmet medical needs in cancer,
including hematological and solid tumors,
and in serious inflammatory conditions***



Thank you for your attention